Education
About Us
Working with TipRanks
Follow Us
Compugen Ltd (CGEN)
NASDAQ:CGEN
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.08Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 04, 2025
|% Change Since: -7.18%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in Compugen's clinical programs, strategic partnerships, and financial stability, which are promising for future growth. However, the company faced revenue declines and a net loss, along with challenges in the TIGIT landscape. Despite these challenges, the strategic advances and strong financial position suggest a cautiously optimistic outlook.Company Guidance
During Compugen's Fourth Quarter and Full Year 2024 Results Conference Call, the company provided guidance on several key metrics and strategic priorities for 2025. Compugen highlighted the advancement of COM701 as a maintenance treatment for platinum-sensitive ovarian cancer, with plans to initiate an adaptive platform trial in the second quarter of 2025. This trial will involve 60 patients and aims to demonstrate a clinically meaningful 3-month improvement in median progression-free survival over the expected 6-month benchmark of the placebo group. Interim analysis results are anticipated in the second half of 2026. Additionally, the company acknowledged setbacks in the TIGIT antibody class but emphasized ongoing Phase III trials with AstraZeneca involving COM902 and rilvegostomig. Compugen's financial position was also addressed, noting a cash balance of approximately $103.3 million as of December 31, 2024, and a cash runway extending into 2027. The company reported $27.9 million in revenues for 2024, with significant contributions from milestone payments related to GS-0321 and rilvegostomig. Research and development expenses decreased, reflecting changes in the classification of costs associated with GS-0321.Advancement of COM701
Data presented in 2024 showed that COM701, in combination with COM902 and pembrolizumab, resulted in encouraging durable responses in platinum-resistant ovarian cancer patients. The company plans to advance COM701 as a maintenance treatment for platinum-sensitive ovarian cancer, with a strategic trial set to start in Q2 2025.
Strategic Partnerships with AstraZeneca and Gilead
Compugen's collaboration with AstraZeneca for rilvegostomig (derived from COM902) includes seven Phase III trials, with potential milestone payments and royalties. Gilead licensed GS-0321, leading to a $30 million milestone payment in 2024 and the initiation of a Phase I trial.
Strong Financial Position
Compugen reported a cash balance of $103.3 million as of December 31, 2024, with a cash runway expected to last into 2027, supporting the company's operating plans and strategic initiatives.
Promising Results for GS-0321
Received FDA IND clearance and initiated a Phase I trial for GS-0321, an anti-IL-18 binding protein antibody, marking progress in their therapeutic pipeline.
---
CGEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CGEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 04, 2025 | $1.81 | $1.68 | -7.18% |
| Nov 12, 2024 | $1.74 | $1.60 | -8.05% |
| Aug 06, 2024 | $1.64 | $1.72 | +4.88% |
| May 20, 2024 | $2.11 | $1.74 | -17.54% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Compugen Ltd (CGEN) report earnings?
Compugen Ltd (CGEN) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Compugen Ltd (CGEN) earnings time?
Compugen Ltd (CGEN) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CGEN EPS forecast?
CGEN EPS forecast for the fiscal quarter 2025 (Q1) is -0.07.
---